What the Mounjaro study evidence actually tells us

Step 1: How the SURMOUNT trials were designed

Clinical trials for weight-management medicines are run in phases. By the time a medicine reaches a phase 3 programme like SURMOUNT, researchers are testing it in large groups of real patients over long periods, not just looking for short-term metabolic changes in a laboratory. SURMOUNT-1, the flagship study for tirzepatide in weight management, randomised 2,539 adults who had obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related condition such as high blood pressure or dyslipidaemia, but who did not have type 2 diabetes. Participants were randomly assigned to once-weekly tirzepatide at 5 mg, 10 mg or 15 mg, or to a placebo injection.

All participants received lifestyle counselling alongside the injections. The trial ran for 72 weeks (roughly 18 months) and measured total body-weight change as the primary outcome. Secondary outcomes included the proportion of participants who lost at least 5%, 10% or 20% of their starting body weight. This structure matters because it means the results reflect medicine plus lifestyle support, not medicine alone. If you look at the full landscape of Mounjaro studies, SURMOUNT-1 sits at the centre of the evidence base.

The trial protocol was registered, peer-reviewed and published in the New England Journal of Medicine. That publication is the source to check if you want to read the methodology in full.

Step 2: Reading the numbers clearly

At the 15 mg dose, SURMOUNT-1 found an average body-weight reduction of around 20–21% at 72 weeks. Roughly one in three participants on the highest dose lost more than 20% of their starting weight. At 10 mg the average was around 19%, and at 5 mg around 16%. The placebo group lost approximately 3% on average, which reflects the effect of the lifestyle support alone.

A few things are worth holding in mind when reading those figures. First, they are averages, some people lost considerably more, others less. Second, 72 weeks is the trial duration; what happens after that is a separate question, and long-term Mounjaro data address weight maintenance in more detail. Third, SURMOUNT-1 excluded people with type 2 diabetes; a separate arm, SURMOUNT-2, looked at that population. The broader tirzepatide clinical programme (SURPASS for diabetes plus SURMOUNT for obesity) involved over 10,000 participants combined, which gives regulators a substantial safety and efficacy dataset to work with.

NICE reviewed this evidence before recommending tirzepatide in December 2024. Their appraisal, TA1026, covers adults with a BMI of at least 35 and at least one weight-related comorbidity for NHS access, though private eligibility under the licensed indications is broader. The distinction between NHS and private thresholds is one a prescriber will talk through with you.

Step 3: The SURMOUNT-5 head-to-head and what it adds

Most clinical trials compare a new medicine against a placebo. SURMOUNT-5 was different: it compared tirzepatide directly against semaglutide 2.4 mg (Wegovy) in 751 adults with obesity and no diabetes, over 72 weeks. The tirzepatide study group achieved greater average weight reduction than the semaglutide group. This is clinically useful because it gives prescribers, and patients, a real-world comparison rather than one inferred from separate trials.

Semaglutide acts on a single gut-hormone receptor; tirzepatide activates two, GIP and GLP-1. Whether that mechanism difference fully explains the weight-loss difference is still being studied. For a fuller picture of the cardiovascular and metabolic evidence, the SUMMIT study looked at tirzepatide in adults with obesity and heart failure, and the SURPASS programme generated the diabetes evidence base. Research into other areas, including tirzepatide's effects in autoimmune conditions, is ongoing.

One practical note on timing: if you are researching this around a busy period (a Monday order before a bank holiday, say) it is worth knowing that treatment at a regulated pharmacy with same-day clinical review still follows fixed dispatch windows, so checking those logistics early avoids a frustrating wait.

What the studies do not tell you, and why a prescriber fills that gap

Trial populations are selected, monitored and supported in ways that do not always mirror everyday life. Participants in SURMOUNT-1 received structured lifestyle counselling throughout; the medicine did not work in isolation. The studies also have specific exclusion criteria: people with a history of pancreatitis, certain thyroid conditions and several other situations were not included, which is one reason a prescriber reviews your personal health history rather than simply applying a BMI number.

Side effects in the trials were predominantly gastrointestinal, nausea, loose stools, constipation and indigestion, most commonly at the start of treatment or after a dose increase, typically settling over days to a couple of weeks. The NHS medicines page for tirzepatide summarises the side-effect profile clearly and is a reliable starting point before any consultation.

If you want to understand the broader picture of what tirzepatide is and how it works before looking at the cost side, the Mounjaro cost page sets out what private treatment typically involves. And if you are ready to talk to a prescriber about whether your health history fits the clinical picture the studies describe, checking your eligibility is the natural next step.